SELLAS Life Sciences Group, Inc. (SLS) Tops Q2 EPS by 5c

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.31), $0.05 better than the analyst estimate of ($0.36).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• Oil near $100, Fed rate fears and Iran tensions - what’s moving markets
• TD Cowen Reiterates Hold Rating on Leidos Holdings (LDOS)